FDA approves NMIBC treatment nogapendekin alfa-inbakicept/BCG
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
The median duration of CR in those who experienced a response to treatment was 26.6 months (95% CI, 9.9-not reached [NR]).
Sponsored by the AUA Young Urologists Committee, the Speed Mentoring program affords residents and fellows the opportunity to meet with an esteemed group of practicing…
The AUA invites the global urologic community to the 119th AUA Annual Meeting in the dynamic city of San Antonio, TX!
You are prohibited from using or uploading content you accessed through this website into external applications, bots, software, or websites, including those using artificial intelligence…
DD01 is a long-acting dual agonist of glucagon-like peptide-1 and glucagon receptors.
Neal D. Shore, MD, shares what he’s most looking forward to at this year’s American Urological Association Annual Meeting.
Adding the radionuclide therapy ¹⁷⁷Lu-PSMA-617 to enzalutamide improved outcomes in patients with treatment-naïve mCRPC in a phase 2 trial.
Topic: Implementation Science in Urologic Oncology: Translating Evidence into Practice Symposium Goal: To introduce Implementation Science to those new to the field, highlight how implementation…
Alicia Morgans presents a meta-analysis, undertaken with colleagues, analyzing 14 phase three trials on treatment intensification in metastatic hormone-sensitive prostate cancer. The study scrutinizes outcomes…
Investigators assessed the monosodium urate burden using 2 ultrasound scoring systems among patients with gout and compared their ability to predict flares.
The largest gathering of residents at the Annual Meeting, this year’s Residents Forum program will feature motivating speakers and interactive discussions with experts in the…